SOURCE: INC Research

INC Research

March 21, 2011 07:00 ET

INC Research to Discuss How CRO-Sponsor Relationships Have and Will Evolve at Partnerships in Clinical Trials 2011

Featured Speakers Offer Insight Into the Changing Role of CROs in the Global Drug Development Environment

RALEIGH, NC--(Marketwire - March 21, 2011) - INC Research, LLC, a therapeutically focused contract research organization (CRO) with a trusted process for delivering reliable results, will feature COO John Potthoff, PhD and Tim Dietlin, VP, Alliance Development, as speakers at this year's Partnerships in Clinical Trials conference in Phoenix, from Mar. 30 to Apr. 1, 2011.

As drug development and outsourcing industries continue to mature and as cost pressures continue to increase, progressive players are starting to look for more value in their relationships. Dietlin will join David Gillogly, global head, Clinical Contracting and Category Management at Novartis, in a discussion on alliance partnership models and how strategic relationships can positively affect performance and outcomes. Specifically, they will explore the definition of clinical delivery alliances and the value these alliance partnership models bring to the drug development process from both the sponsor and CRO perspective.

Dietlin and Gillogly's session, "The Value of Strategic Alliances vs. Transactional CRO-Sponsor Relationships" will be held on Mar. 31st at 3:00 p.m.

For the past several years, an economic recession, mergers and acquisitions, patent cliffs, product pipeline rationalizations, and changes in the way pharmaceutical companies invest in R&D have been impacting the healthcare industry. COO John Potthoff, a seasoned executive with extensive experience within the global life sciences and contract services sector, will participate alongside top industry executives from VDDI Pharmaceuticals, UBC and Pfizer in a moderated panel discussion on the industry's future.

The session will look at macroeconomic trends, strategies, and practices as well as analogies drawn from other R&D intensive industries to project where sponsor-CRO relationships are headed. Potthoff will discuss some of the recent factors driving change in the industry and explore new business paradigms for partnering with clients to enhance value and expedite drug development.

Potthoff's session, "Industry Future - C-Suite Fireside Chat," will be held on Apr. 1 at 1:30 p.m. and will be moderated by Peter Pitts, president of the Center for Medicine in the Public Interest.

INC Research is a privately held, therapeutically focused global CRO with deep expertise in managing global Phase I through Phase IV clinical development programs. INC Research employs more than 2,000 people in 40 countries worldwide. The full-service CRO was recently ranked 10th on the list of Preferred CROs, an annual survey conducted by William Blair and was number 10 on the Scrip Clinical Research 25 list based on 2009 revenues.

About INC Research, LLC
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit www.incresearch.com or follow us at @inc_research.

Contact Information